Ranbaxy shakes up its executive ranks for manufacturing oversight

After years of manufacturing lapses left it with four of its 5 FDA-approved plants banned, a consent decree and now a deal to be sold, Ranbaxy Laboratories has cleaned house in its quality oversight ranks. The Economic Times reports that the company has promoted Arno Gessner to head global quality, replacing Dale Adkisson. Adkisson had been hired in 2010 to help the company fix its quality issues, but in the years since, problems with FDA concerns have mounted, leading the agency to ban two plants since last year and to a deal for Sun Pharmaceutical to buy Ranbaxy for $3.2 billion. Story | More